Pongamol

Pongamol

SCHEMBL900825

COc1c(C(=O)/C=C(\O)c2ccccc2)ccc2occc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 5/20 1.00
CYP1B1 Q16678 5/20 1.00
ABCB1 P08183 1/20 1.00
CYP1A2 P05177 1/20 0.65
KCNA3 P22001 6/20 0.46
NLRP3 Q96P20 1/20 0.46
KDM4E B2RXH2 2/20 0.44
CYP3A4 P08684 2/20 0.44
MAPT P10636 2/20 0.44
HPGD P15428 2/20 0.44
ALDH1A1 P00352 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
TSHR P16473 1/20 0.44
MAPK1 P28482 1/20 0.44
CYP2C19 P33261 1/20 0.44
HSD17B10 Q99714 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
NFE2L2 Q16236 1/20 0.43
PTPN1 P18031 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ovalitenone SCHEMBL29598773 0.82 CYP1A1 (1.00) CYP1A1CYP1B1ABCB1CYP1A2KDM4E
SCHEMBL31707548 0.80 CYP1A1 (0.67) CYP1A1CYP1B1ABCB1CYP1A2KCNA3
SCHEMBL900826 0.79 CYP1A1 (1.00) CYP1A1CYP1B1ABCB1CYP1A2KCNA3
SCHEMBL29664148 0.79 CYP1A1 (1.00) CYP1A1CYP1B1ABCB1CYP1A2KCNA3
SCHEMBL28738857 0.75 CYP1A1 (0.60) CYP1A1CYP1B1ABCB1KDM4ECYP3A4
SCHEMBL29639598 0.75 CYP1A1 (0.60) CYP1A1CYP1B1ABCB1CYP1A2KCNA3
SCHEMBL2045384 0.74 CYP1A1 (0.63) CYP1A1CYP1B1ABCB1CYP1A2KCNA3
SCHEMBL28738867 0.72 CYP1A1 (0.56) CYP1A1CYP1B1ABCB1CYP1A2KDM4E
SCHEMBL29639600 0.72 CYP1A1 (0.55) CYP1A1CYP1B1ABCB1CYP1A2KDM4E
SCHEMBL28738865 0.72 CYP1A1 (0.55) CYP1A1CYP1B1ABCB1CYP1A2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 397 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026099270-A1 BIODEGRADABLE UV ABSORBERS AND USES THEREOF II BASF SE (DE) 2026-05-15 WO claimed
EP-4732823-A1 COSMETIC PREPARATION Laverana GmbH & Co. KG (DE) 2026-04-29 EP claimed
US-12610971-B2 Pongamia compositions, methods of preparing and analyzing thereof, and uses thereof TerViva BioEnergy, Inc. (US) 2026-04-28 US claimed
US-20260076366-A1 SYNERGISTIC PESTICIDAL COMPOSITIONS AND METHODS FOR DELIVERY OF ACTIVE INGREDIENTS 0903608 B C LTD (CA) 2026-03-19 US claimed
EP-4687823-A1 COMPOSITION USEFUL FOR SLOWING DOWN DEGRADATION CAUSED BY LIGHT, HEAT AND/OR THE OXIDATION OF AN ACTIVE COMPOUND Sensient Cosmetic Technologies (FR) 2026-02-11 EP claimed
US-20250367107-A1 SUNSCREEN COMPOSITION INCLUDING A SALICYLATE AND PONGAMIA PINNATA SEED EXTRACT EDGEWELL PERSONAL CARE BRANDS LLC (US) 2025-12-04 US claimed
WO-2025242899-A1 SUBSTITUTED CINNAMIC ACID DERIVATIVES AS UV ABSORBERS AND USES THEREOF BASF SE (DE) 2025-11-27 WO claimed
WO-2025242884-A1 SUBSTITUTED CINNAMIC ACID DERIVATIVES AS UV ABSORBERS AND USES THEREOF BASF SE (DE) 2025-11-27 WO claimed
WO-2025242885-A1 SUBSTITUTED CINNAMIC ACID DERIVATIVES AS UV ABSORBERS AND USES THEREOF BASF SE (DE) 2025-11-27 WO claimed
WO-2025242892-A1 SUBSTITUTED CINNAMIC ACID DERIVATIVES AS UV ABSORBERS AND USES THEREOF BASF SE (DE) 2025-11-27 WO claimed
WO-2017013264-A1 PROCESS FOR PONGAMOL ENRICHMENT OF KARANJA OIL BIOSYNTHIS (FR) 2017-01-26 WO claimed
WO-2016016540-A2 SOLAR FILTER PROMOTING AGENTS INNOVI (FR) 2016-02-04 WO claimed
WO-2014114888-A2 ALTERNATIVE SYSTEM FOR PROTECTION AGAINST UV RADIATION AND FREE RADICALS THOREL JEAN-NOëL (FR) 2014-07-31 WO claimed
WO-2012119860-A1 COSMETIC COMPOSITION CONTAINING A DIBENZOYLMETHANE DERIVATIVE AND A MONOESTER-MONOAMIDE COMPOUND OF METHYLSUCCINIC ACID; PROCESS FOR PHOTOSTABILIZING A DIBENZOYLMETHANE DERIVATIVE L'OREAL (FR) 2012-09-13 WO claimed
US-20110206789-A1 HERBAL EXTRACT PRODUCTS AND METHODS (as amended) PRIME INTERACTION HOLDINGS LIMITED (LI) 2011-08-25 US claimed
WO-2011027362-A2 A HERBAL ANTI-TERMITE FORMULATION KUMAR VISHAL (IN) 2011-03-10 WO claimed
EP-0521651-B1 Sunscreen composition UNILEVER PLC (GB) 1996-08-21 EP claimed
EP-0431755-B1 Cosmetic composition UNILEVER PLC (GB) 1994-01-26 EP claimed
EP-0521651-A2 Sunscreen composition UNILEVER PLC (GB) 1993-01-07 EP claimed
EP-0431755-A1 Cosmetic composition UNILEVER PLC (GB) 1991-06-12 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12610971-B2 Pongamia compositions, methods of preparing and analyzing thereof, and uses thereof DEK, DGKG, SRMS CYP1A1 2801/4885CYP1B1 3735/4885ABCB1 4748/4885
US-20260076366-A1 SYNERGISTIC PESTICIDAL COMPOSITIONS AND METHODS FOR DELIVERY OF ACTIVE INGREDIENTS TACR3, GSTO1, TIAL1 CYP1A1 1148/4885CYP1B1 469/4885ABCB1 1041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.